103 related articles for article (PubMed ID: 22484690)
1. Neuropeptide Y Y1 receptor antagonism increases bone mass in mice.
Sousa DM; Baldock PA; Enriquez RF; Zhang L; Sainsbury A; Lamghari M; Herzog H
Bone; 2012 Jul; 51(1):8-16. PubMed ID: 22484690
[TBL] [Abstract][Full Text] [Related]
2. Critical interplay between neuropeptide Y and sex steroid pathways in bone and adipose tissue homeostasis.
Allison SJ; Baldock PA; Enriquez RF; Lin E; During M; Gardiner EM; Eisman JA; Sainsbury A; Herzog H
J Bone Miner Res; 2009 Feb; 24(2):294-304. PubMed ID: 18847327
[TBL] [Abstract][Full Text] [Related]
3. Energy metabolic profile of mice after chronic activation of central NPY Y1, Y2, or Y5 receptors.
Henry M; Ghibaudi L; Gao J; Hwa JJ
Obes Res; 2005 Jan; 13(1):36-47. PubMed ID: 15761161
[TBL] [Abstract][Full Text] [Related]
4. Neuropeptide Y1 receptor antagonism protects β-cells and improves glycemic control in type 2 diabetes.
Yang CH; Ann-Onda D; Lin X; Fynch S; Nadarajah S; Pappas EG; Liu X; Scott JW; Oakhill JS; Galic S; Shi Y; Moreno-Asso A; Smith C; Loudovaris T; Levinger I; Eizirik DL; Laybutt DR; Herzog H; Thomas HE; Loh K
Mol Metab; 2022 Jan; 55():101413. PubMed ID: 34890851
[TBL] [Abstract][Full Text] [Related]
5. Critical role for Y1 receptors in mesenchymal progenitor cell differentiation and osteoblast activity.
Lee NJ; Doyle KL; Sainsbury A; Enriquez RF; Hort YJ; Riepler SJ; Baldock PA; Herzog H
J Bone Miner Res; 2010 Aug; 25(8):1736-47. PubMed ID: 20200977
[TBL] [Abstract][Full Text] [Related]
6. Orexigenic effect of the melanocortin MC4 receptor antagonist HS014 is inhibited only partially by neuropeptide Y Y1 receptor selective antagonists.
Kask A; Schiöth HB; Harro J; Wikberg JE; Rägo L
Can J Physiol Pharmacol; 2000 Feb; 78(2):143-9. PubMed ID: 10737677
[TBL] [Abstract][Full Text] [Related]
7. Hypothalamic regulation of cortical bone mass: opposing activity of Y2 receptor and leptin pathways.
Baldock PA; Allison S; McDonald MM; Sainsbury A; Enriquez RF; Little DG; Eisman JA; Gardiner EM; Herzog H
J Bone Miner Res; 2006 Oct; 21(10):1600-7. PubMed ID: 16995815
[TBL] [Abstract][Full Text] [Related]
8. Synergistic interaction between neuropeptide Y1 and Y5 receptor pathways in regulation of energy homeostasis.
Mashiko S; Moriya R; Ishihara A; Gomori A; Matsushita H; Egashira S; Iwaasa H; Takahashi T; Haga Y; Fukami T; Kanatani A
Eur J Pharmacol; 2009 Aug; 615(1-3):113-7. PubMed ID: 19482021
[TBL] [Abstract][Full Text] [Related]
9. Hypothalamic control of bone formation: distinct actions of leptin and y2 receptor pathways.
Baldock PA; Sainsbury A; Allison S; Lin EJ; Couzens M; Boey D; Enriquez R; During M; Herzog H; Gardiner EM
J Bone Miner Res; 2005 Oct; 20(10):1851-7. PubMed ID: 16160743
[TBL] [Abstract][Full Text] [Related]
10. Neuropeptide Y Y1 receptors in the central nucleus of amygdala mediate the anxiolytic-like effect of allopregnanolone in mice: Behavioral and immunocytochemical evidences.
Deo GS; Dandekar MP; Upadhya MA; Kokare DM; Subhedar NK
Brain Res; 2010 Mar; 1318():77-86. PubMed ID: 20059983
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226.
Doods HN; Wienen W; Entzeroth M; Rudolf K; Eberlein W; Engel W; Wieland HA
J Pharmacol Exp Ther; 1995 Oct; 275(1):136-42. PubMed ID: 7562541
[TBL] [Abstract][Full Text] [Related]
12. Characterization of neuropeptide Y-induced feeding in mice: do Y1-Y6 receptor subtypes mediate feeding?
Iyengar S; Li DL; Simmons RM
J Pharmacol Exp Ther; 1999 May; 289(2):1031-40. PubMed ID: 10215684
[TBL] [Abstract][Full Text] [Related]
13. Potent and selective tools to investigate neuropeptide Y receptors in the central and peripheral nervous systems: BIB03304 (Y1) and CGP71683A (Y5).
Dumont Y; Cadieux A; Doods H; Fournier A; Quirion R
Can J Physiol Pharmacol; 2000 Feb; 78(2):116-25. PubMed ID: 10737674
[TBL] [Abstract][Full Text] [Related]
14. Osteoblast specific Y1 receptor deletion enhances bone mass.
Lee NJ; Nguyen AD; Enriquez RF; Doyle KL; Sainsbury A; Baldock PA; Herzog H
Bone; 2011 Mar; 48(3):461-7. PubMed ID: 21040809
[TBL] [Abstract][Full Text] [Related]
15. Central NPY receptor-mediated alteration of heart rate dynamics in mice during expression of fear conditioned to an auditory cue.
Tovote P; Meyer M; Beck-Sickinger AG; von Hörsten S; Ove Ogren S; Spiess J; Stiedl O
Regul Pept; 2004 Aug; 120(1-3):205-14. PubMed ID: 15177939
[TBL] [Abstract][Full Text] [Related]
16. Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activity.
Iida-Klein A; Lu SS; Cosman F; Lindsay R; Dempster DW
Bone; 2007 Feb; 40(2):391-8. PubMed ID: 17056311
[TBL] [Abstract][Full Text] [Related]
17. Neuropeptide Y Y2 antagonist treated ovariectomized mice exhibit greater bone mineral density.
Seldeen KL; Halley PG; Volmar CH; Rodríguez MA; Hernandez M; Pang M; Carlsson SK; Suva LJ; Wahlestedt C; Troen BR; Brothers SP
Neuropeptides; 2018 Feb; 67():45-55. PubMed ID: 29129406
[TBL] [Abstract][Full Text] [Related]
18. The neuropeptide Y (NPY) Y1 receptor antagonist BIBP 3226: equal effects on vascular responses to exogenous and endogenous NPY in the pig in vivo.
Malmström RE; Balmér KC; Lundberg JM
Br J Pharmacol; 1997 Jun; 121(3):595-603. PubMed ID: 9179405
[TBL] [Abstract][Full Text] [Related]
19. Evidence for involvement of neuropeptide Y receptors in the regulation of food intake: studies with Y1-selective antagonist BIBP3226.
Kask A; Rägo L; Harro J
Br J Pharmacol; 1998 Aug; 124(7):1507-15. PubMed ID: 9723965
[TBL] [Abstract][Full Text] [Related]
20. Co-expression of neuropeptide Y Y1 and Y5 receptors results in heterodimerization and altered functional properties.
Gehlert DR; Schober DA; Morin M; Berglund MM
Biochem Pharmacol; 2007 Dec; 74(11):1652-64. PubMed ID: 17897631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
